Structured Follow-up Care for Children Who Survived Blood Cancers
Studies a structured follow-up plan for childhood leukemia and lymphoma survivors in China.
Plain-language title generated from the registry record
Registry title: HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
Key facts
- Where
- Hangzhou and Ningbo, ChinaSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people who had a blood cancer such as leukemia or lymphoma and finished their main treatment at least 12 months ago. They will be followed to track late effects of the illness and treatment.
- Age
- 1 to 21 years
- Sex
- All sexes can join.
- Disease stage
- Childhood blood cancer (ALL, AML, lymphoma, etc.) with main treatment finished.
- Earlier treatment
- Primary treatment completed at least 12 months ago.
Main reasons for not taking part
- Severe organ failure that prevents follow-up
- Major genetic or body-wide disease that affects growth or organ function
- Expected poor compliance with follow-up or refusal to take part
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 21 years old?
Source: NCT07483749, who can take part
Where in China
- Children's Hospital, Zhejiang University School of MedicineHangzhou, ChinaNo longer taking part
- Hangzhou Children's HospitalHangzhou, ChinaNo longer taking part
- Affiliated Women and Children's Hospital of Ningbo UniversityNingbo, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The Children's Hospital of Zhejiang University School of Medicine
- Trial code
- NCT07483749
- Record updated
- 19 March 2026
- Original description
This study aims to construct a structuralized follow-up model for survivors of childhood hematological malignancies in China. Using a multicenter prospective cohort design, it will identify the burden and risk factors of late effects. The study hypothesizes that a standardized follow-up path managed by an electronic platform will improve follow-up compliance and reduce the missed diagnosis rate of late effects.Read full original descriptionShow less
A Multicenter Prospective Study on Structuralized Follow-up Model Construction and Late Effect Burden of Childhood Hematological Malignancy Survivors (HEM-SURVIVE)
This study aims to construct a structuralized follow-up model for survivors of childhood hematological malignancies in China. Using a multicenter prospective cohort design, it will identify the burden and risk factors of late effects. The study hypothesizes that a standardized follow-up path managed by an electronic platform will improve follow-up compliance and reduce the missed diagnosis rate of late effects.
Inclusion: Diagnosed with childhood hematological malignancies (ALL, AML, Lymphoma, etc.), Completed primary treatment for ≥12 months; Age 1-21 years; Capable of completing follow-up and data collection; Informed consent signed.
Exclusion: Severe organ failure preventing follow-up; Major genetic or systemic diseases affecting growth/organ function; Expected poor compliance or refusal to participate.